DCA09: VS-041-102 - Clinical Trial
What is the Purpose of this Study?
This is a randomized trial, with some participants receiving the study drug and some receiving placebo. The study drug (an oral pill) will be taken daily for 28 days. The total duration of study activities is 9 weeks.
This study is enrolling patients with Heart Failure with Preserved Ejection Fraction (HFpEF).
Who Can Participate in the Study?
People can join this study if they are over 50 years old and have a type of heart failure called HFpEF, which means the heart pumps well but does not relax and fill properly. They cannot have other serious heart conditions, such as valve problems, diseases of the heart lining, or weakened heart muscle. They also cannot have had recent heart attacks, blocked heart arteries, abnormal heart rhythms, or major heart surgery. People with certain implanted heart devices are also not able to join this study.
What is Involved?
This trial is testing the safety and tolerability of a novel drug that targets the fibrosis (hardening or scarring) that occurs in patients with heart failure.
Study Details
